# Milestone

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/milestone

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.miles-bio.com
- Total disclosed funding: $27M
- Latest round: Series A (Jan 3, 2025)
- Investors on record: 8

## About

Established in 2014 and based in Shanghai, China, Milestone operates as a biomedical company that focuses on providing cell gene therapy and related services. It has R&D and production centers in Beijing, Shenzhen, and Zhejiang. It was recognized as the National High-tech enterprise. Jinbao Zhang, the company's founder and CEO, graduated from Jiangxi University of Traditional Chinese Medicine and has nearly 20 years of entrepreneurial and work experience in the upstream life sciences. In January 2025, Milestone raised a series A+ funding for approximately CNY 100 million.

The company mainly focuses on the clinical application market of stem cells, engaging in the isolation, culture and optimization of neurons, glial cells, neuroblastoma cells, and other types of primary cells. Its products and services are divided into three series, which are cell separation service platforms, drug development platforms, and cell culture platforms. Platforms and services within include liver cell isolation service, in vitro drug efficacy evaluation platform, and cell culture supporting reagents.

The company will use the series A+ funding for the development of a series of primary cell models, supporting reagents and consumables, and scientific research business, as well as the expansion of overseas business scope. The company plans to launch more innovative products and expand its market in 2025.

The company generates revenue by providing cell gene therapy services.

## Funding rounds

- Series A, Jan 3, 2025, $14M — Jinan High-Tech Financial Investment, Nanjing Innovation Capital Group, Industrial Securities Capital
- Series A, Aug 22, 2023, $14M — Addor Capital, Shanghai Titan Scientific Co., Ltd., GL Ventures, Haichuang Tiancheng Capital, Tongyu Fund

## Investors

- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Shanghai Titan Scientific Co., Ltd. — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- Haichuang Tiancheng Capital (https://capitalatlas.ai/funds/haichuang-tiancheng-capital) — Series A
- Tongyu Fund — Series A
- Jinan High-Tech Financial Investment — Series A
- Nanjing Innovation Capital Group — Series A
- Industrial Securities Capital — Series A